Buspirone 5/10/15/30 mg tabs — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Generalized Anxiety Disorder / Panic Disorder

• Escitalopram
• Sertraline
• Escitalopram 5/10/20 mg tabs
• Sertraline 25/50/100 mg tabs

About Buspirone 5/10/15/30 mg tabs

Buspirone, available in 5, 10, 15, and 30 mg tablets, offers a unique approach to managing anxiety without the typical concerns associated with some other medications. At TheDrugClub, we believe managing your health shouldn't add to your stress. Discover how our members can access buspirone with significant savings and ultimate convenience.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Buspirone 5/10/15/30 mg tabs is approved for (FDA label)

Buspirone hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety. Anxiety or tension associated with the stress of everyday life usually does not require treatment with an anxiolytic. The efficacy of buspirone hydrochloride tablets has been demonstrated in controlled clinical trials of outpatients whose diagnosis roughly corresponds to Generalized Anxiety Disorder (GAD). Many of the patients enrolled in these studies also had coexisting depressive symptoms and buspirone hydrochloride tablets relieved anxiety in the presence of these coexisting depressive symptoms. The patients evaluated in these studies had experienced symptoms for periods of 1 month to over 1 year prior to the study, with an average symptom duration of 6 months.

Source: Read the full FDA label on DailyMed. Label effective date: May 15, 2024.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Buspirone 5/10/15/30 mg tabs (FDA label)

(See also PRECAUTIONS .) Commonly Observed The more commonly observed untoward events associated with the use of buspirone hydrochloride tablets not seen at an equivalent incidence among placebo-treated patients include dizziness, nausea, headache, nervousness, lightheadedness, and excitement. Associated with Discontinuation of Treatment One guide to the relative clinical importance of adverse events associated with buspirone hydrochloride tablets is provided by the frequency with which they caused drug discontinuation during clinical testing. Approximately 10% of the 2200 anxious patients who participated in the buspirone hydrochloride tablets premarketing clinical efficacy trials in anxiety disorders lasting 3 to 4 weeks discontinued treatment due to an adverse event.

Source: FDA prescribing information (DailyMed). Set ID: 18e90d65-4a3a-864e-e063-6294a90ae99d. SPL document ID: 18e9092c-7992-80e0-e063-6294a90a73fb. Label effective date: May 15, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Buspirone 5/10/15/30 mg tabs (FDA label)

Buspirone hydrochloride tablets are contraindicated in patients hypersensitive to buspirone hydrochloride. The use of monoamine oxidase inhibitors (MAOIs) intended to treat depression with buspirone or within 14 days of stopping treatment with buspirone is contraindicated because of an increased risk of serotonin syndrome and/or elevated blood pressure. The use of buspirone within 14 days of stopping an MAOI intended to treat depression is also contraindicated. Starting buspirone in a patient who is being treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS , DOSAGE AND ADMINISTRATION and DRUG INTERACTIONS ).

Source: FDA prescribing information (DailyMed). Set ID: 18e90d65-4a3a-864e-e063-6294a90ae99d. SPL document ID: 18e9092c-7992-80e0-e063-6294a90a73fb. Label effective date: May 15, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Buspirone 5/10/15/30 mg tabs (FDA label)

Psychotropic Agents MAO inhibitors The use of monoamine oxidase inhibitors (MAOIs) intended to treat depression with buspirone or within 14 days of stopping treatment with buspirone is contraindicated because of an increased risk of serotonin syndrome and/or elevated blood pressure. The use of buspirone within 14 days of stopping an MAOI intended to treat depression is also contraindicated. Starting buspirone in a patient who is being treated with reversible MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome (see WARNINGS , DOSAGE AND ADMINISTRATION AND CONCOMITANT DRUG ). Amitriptyline After addition of buspirone to the amitriptyline dose regimen, no statistically significant differences in the steady-state pharmacokinetic parameters (C max , AUC, and C min ) of amitriptyline or its metabolite nortriptyline were observed.

Source: FDA prescribing information (DailyMed). Set ID: 18e90d65-4a3a-864e-e063-6294a90ae99d. SPL document ID: 18e9092c-7992-80e0-e063-6294a90a73fb. Label effective date: May 15, 2024. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.